BACKGROUND: DNA sequence amplifications are involved in the progression of many tumor types, and have also been found in advanced prostate cancer. The aim of this study was to detect new loci of DNA amplifications in prostate cancer. METHODS: Comparative genomic hybridization (CGH) was used for whole genome screening of DNA sequence copy number alterations in 27 advanced prostate cancers. RESULTS: The most prevalent changes were losses of 8p, 13q (52%, each), 6q (48%), 18q (37%), 5q (30%), 2q, 4q and 16q (26%, each), and gains of 8q (48%), Xq (40%), and Xp (26%). In addition, 16 high-level amplifications were found. These included Xq12 (five), 8q24 (two), and 11q13 (one) with known putative target genes (androgen receptor, MYC and Cyclin D1), and 1q21-25 (three), 10q22 (two), 17q23-24 (two), and 8q21 (one) where the target genes remain unknown. CONCLUSIONS: High-level amplifications at different chromosomal sites occur in advanced prostate cancer. The detection of amplified chromosomal regions may serve as a starting point to discover novel oncogenes involved in prostate cancer progression. Copyright 2001 Wiley-Liss, Inc.
BACKGROUND: DNA sequence amplifications are involved in the progression of many tumor types, and have also been found in advanced prostate cancer. The aim of this study was to detect new loci of DNA amplifications in prostate cancer. METHODS: Comparative genomic hybridization (CGH) was used for whole genome screening of DNA sequence copy number alterations in 27 advanced prostate cancers. RESULTS: The most prevalent changes were losses of 8p, 13q (52%, each), 6q (48%), 18q (37%), 5q (30%), 2q, 4q and 16q (26%, each), and gains of 8q (48%), Xq (40%), and Xp (26%). In addition, 16 high-level amplifications were found. These included Xq12 (five), 8q24 (two), and 11q13 (one) with known putative target genes (androgen receptor, MYC and Cyclin D1), and 1q21-25 (three), 10q22 (two), 17q23-24 (two), and 8q21 (one) where the target genes remain unknown. CONCLUSIONS: High-level amplifications at different chromosomal sites occur in advanced prostate cancer. The detection of amplified chromosomal regions may serve as a starting point to discover novel oncogenes involved in prostate cancer progression. Copyright 2001 Wiley-Liss, Inc.
Authors: Claire L Simpson; Cheryl D Cropp; Tiina Wahlfors; Asha George; Marypat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Teuvo Tammela; Johanna Schleutker; Joan E Bailey-Wilson Journal: Eur J Hum Genet Date: 2012-09-05 Impact factor: 4.246
Authors: O Saramäki; N Willi; O Bratt; T C Gasser; P Koivisto; N N Nupponen; L Bubendorf; T Visakorpi Journal: Am J Pathol Date: 2001-12 Impact factor: 4.307
Authors: Claus L Andersen; Outi Monni; Urs Wagner; Juha Kononen; Maarit Bärlund; Christoph Bucher; Philippe Haas; Antonio Nocito; Heidi Bissig; Guido Sauter; Anne Kallioniemi Journal: Am J Pathol Date: 2002-07 Impact factor: 4.307
Authors: Xiaolu Pan; Xuemin Lu; Xin Lu; Chang-Jiun Wu; Di Zhao; Shan Feng; Yong Zang; Rumi Lee; Sunada Khadka; Samirkumar B Amin; Eun-Jung Jin; Xiaoying Shang; Pingna Deng; Yanting Luo; William R Morgenlander; Jacqueline Weinrich; Shan Jiang; Qing Chang; Nora M Navone; Patricia Troncoso; Ronald A DePinho; Y Alan Wang Journal: Cancer Res Date: 2018-05-16 Impact factor: 12.701
Authors: Bassem R Haddad; Lei Gu; Tuomas Mirtti; Ayush Dagvadorj; Paraskevi Vogiatzi; David T Hoang; Renu Bajaj; Benjamin Leiby; Elyse Ellsworth; Shauna Blackmon; Christian Ruiz; Mark Curtis; Paolo Fortina; Adam Ertel; Chengbao Liu; Hallgeir Rui; Tapio Visakorpi; Lukas Bubendorf; Costas D Lallas; Edouard J Trabulsi; Peter McCue; Leonard Gomella; Marja T Nevalainen Journal: Am J Pathol Date: 2013-05-07 Impact factor: 4.307